Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Klotho inhibits renal ox-LDL deposition via IGF-1R/RAC1/OLR1 signaling to ameliorate podocyte injury in diabetic kidney disease

Fig. 3

RAC1 was involved in the pathway of Klotho regulating podocytic ox-LDL deposition in DKD. A TEM was used to assess the morphological changes of mitochondria in podocytes of WT DKD, KL+/− DKD and TgKL DKD. B, C IF analysis using WT1 and Nephrin was employed to examine the RAC1 expression in the kidneys of DKD patients and mice, compared to HC and WT groups. D IF analysis using WT1 and Nephrin was conducted to evaluate the impact of Klotho on RAC1 expression in podocytes of WT DKD, KL+/− DKD and TgKL DKD, respectively. E Western blot was utilized to determine the expression of RAC1 in the absence or presence of Klotho in DKD. F Analysis of RAC1 expression and podocytic ox-LDL deposition was conducted by administering the RAC1 inhibitor (1A-116) and agonist (DA-MED) on KL+/− DKD and TgKL DKD, respectively. ns no significant; *P < 0.05; **P < 0.01; ***P < 0.001

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840